Aminoglycoside-associated nephrotoxicity in the elderly

Annals of Pharmacotherapy

Volumn 37, Issue 2, 2003, Pages 182-186

  Baciewicz, Anne M ^a   Sokos, Denise R ^b   Cowan, Ronald I ^c   Morand, Brenda R ^c   Mallet, Louise ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^c NONE

Author keywords

Aminoglycosides; Elderly; Multiple dose; Nephrotoxicity; Single dose

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; CONTRAST MEDIUM; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GENTAMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; TOBRAMYCIN; VANCOMYCIN;

AGED; AGING; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; HYDRATION; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0037312587     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002800303700203     Document Type: Article

References (14)

1. Vanhaeverbeek M, Siska G, Douchamps J. Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol 1993;31:153-6.
2. Koo J, Tight R, Rajkumar V, Hawa Z. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 1996;101:177-83.
3. Segarra-Newnham M. Use of large-dose gentamicin regimens in elderly men. Hosp Pharm 1999;34:420-2.
4. Paterson DL, Robson JMB, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998;13:735-9.
5. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Q J Med 2002;95:291-7.
6. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-63.
7. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996;53:1141-50.
8. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults:a meta-analysis. Ann Intern Med 1996;124:717-25.
9. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-44.
10. Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48:39-43.
11. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-95.
12. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809.
13. Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy 1997;17:810-4.
14. Mithani H, Brown G. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics 1996;10:494-503.